Faricimab-svoa

(Vabysmo®)

Faricimab-svoa

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravitreal; 120 mg/Ml)
Drug ClassVascular endothelial growth factors and angiopoietin-2 inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
  • Indicated for the treatment of patients with Diabetic Macular Edema (DME).
  • Indicated for the treatment of patients with Macular Edema following Retinal Vein Occlusion (RVO).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Faricimab-svoa (Vabysmo) is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration, Diabetic Macular Edema, and Macular Edema following Retinal Vein Occlusion.
  • Four studies were analyzed to gather information about this drug.
  • In terms of efficacy and safety in treating Diabetic Macular Edema, faricimab-svoa showed superior retinal drying, fewer injections needed, and better visual acuity outcomes compared to ranibizumab and bevacizumab.
  • However, for Neovascular Age-related macular degeneration treatment, brolucizumab demonstrated superior retinal thickness reduction compared to faricimab-svoa.
  • The Treat & Extend regimen of Vabysmo allows up to 16-week intervals between treatments, which could improve adherence due to its reduced injection frequency without compromising efficacy or safety.
  • Detailed subgroup analyses are necessary for a comprehensive understanding of Vabysmo's comparative performance, especially regarding treatment-naive patients and longer-term outcomes beyond two years.